ASX-Dividend-Report-Banner

Apollo Hospitals Unveils South Asia's First ZAP-X, Transforming Brain Tumor Care

March 11, 2024 06:00 PM AEDT | By Cision
 Apollo Hospitals Unveils South Asia's First ZAP-X, Transforming Brain Tumor Care
Image source: Kalkine Media

NEW DELHI, March 11, 2024 /PRNewswire/ -- Apollo Hospitals becomes the first hospital to introduce ZAP-X Gyroscopic Radiosurgery Platform, a significant milestone as the first in South Asia to introduce this ground-breaking technology. ZAP-X introduces a new era in brain tumor treatment, offering patients a non-invasive, pain-free alternative with sessions lasting just 30 minutes.

Prof. John R. Adler, Founder and CEO, Zap Surgical and Professor of Neurosurgery, Stanford School of Medicine and Dr Prathap Chandra Reddy, Founder Chairman, Apollo Hospitals Group at the launch of Zap-X Gyroscopic Radiosurgery Platform in New Delhi
Prof. John R. Adler, Founder and CEO, Zap Surgical and Professor of Neurosurgery, Stanford School of Medicine and Dr Prathap Chandra Reddy, Founder Chairman, Apollo Hospitals Group at the launch of Zap-X Gyroscopic Radiosurgery Platform in New Delhi

This transformative technology redefines precision with minimal radiation exposure, enabling new standards in effectiveness and patient comfort. Unlike conventional methods, ZAP-X utilizes a self-shielded, gyroscopic linear accelerator design, to direct radiosurgical beams from thousands of potential angles, accurately focusing radiation on the intended tumor or target. Moreover, traditional brain surgeries, lasting 3-4 hours, are replaced by ZAP-X's single-session treatment of no more than 30 minutes, facilitating day-care procedures and allowing patients to return home post-treatment, unlike traditional surgeries requiring extended hospitalization and anesthesia. ZAP-X demonstrates high success, ensuring effective control and relief for various conditions with minimal side effects, achieving over 95% control rate in 10 years and an exceptional 99.4% control rate in 5 years for small, defined tumors. These proven clinical capabilities enable neurologists and neurosurgeons to treat various conditions with better accuracy and fewer side effects.

Dr Prathap Chandra Reddy, Founder Chairman, Apollo Hospitals Group said, "For four decades, Apollo Hospitals has pioneered healthcare, advancing exceptional care. We pledge to democratize technology, making it accessible to all citizens and global communities, elevating standards of brain tumor treatment and ensuring better quality of life. ZAP-X strengthens the battle against Non-Communicable Diseases, especially cancers with superior outcomes."

Prof. John R. Adler, Founder and CEO, Zap Surgical and Professor of Neurosurgery, Stanford School of Medicine said, "Stereotactic radiosurgery is among the most important medical advancements of the past century. Eligible patients no longer must experience debilitating surgical resections, or potentially lose cognitive capacity by undergoing whole-brain radiotherapy. Instead, with ZAP-X radiosurgery, patients can now be quickly treated in an outpatient setting and often return to normal activities the same day with no incisions, and no pain."

The Apollo Institute of Neurosciences pioneers neurological care in India and beyond, boasting advanced facilities and over 180,000 successful neurosurgeries. With smart technology, stroke protocols are revolutionized for faster, precise treatment. Supported by 300+ specialists, Apollo annually treats 25,000 patients. The unveiling of the ZAP-X platform reaffirms Apollo's commitment to spearheading innovations that transform lives. 

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.